Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Telomelysin (development code: OBP-301)
Applicable field (uses covered by this announcement)
For purposes of public health insurance, handled in accordance with the provisions applicable to pharmaceuticals
Launch dateFrom the fiscal year ending December 2026 (planned)
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
The parties have a business relationship through the sale of Telomelysin. Sales are planned to be conducted through FUJIFILM Toyama Chemical Co., Ltd.
CounterpartyFUJIFILM Toyama Chemical Co., Ltd.
Impact on Business Performance
No impact on the Company's financial results from this matter
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
Central Social Insurance Medical Council
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin (development code: OBP-301) |
| Counterparty | FUJIFILM Toyama Chemical Co., Ltd. |
| Relationship with the Company | The parties have a business relationship through the sale of Telomelysin. Sales are planned to be conducted through FUJIFILM Toyama Chemical Co., Ltd. |
| Launch date | From the fiscal year ending December 2026 (planned) |
| Applicable area | For purposes of public health insurance, handled in accordance with the provisions applicable to pharmaceuticals |
| Impact on Business Performance | No impact on the Company's financial results from this matter |
| Source | Central Social Insurance Medical Council |
Items this document does not state (11)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Telomelysin is expected to provide therapeutic benefits through methods of use and pharmacological effects similar to those of pharmaceuticals.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.